Why the study?
Overeating disorders largely contribute to worldwide incidences of obesity, and available treatments are limited.
Does chemogenetic activation or CACNA2D1 overexpression in vlPAG GABAergic cells reverse obesity in high-fat diet-induced obesity mice?
Does chemogenetic activation or CACNA2D1 overexpression in vlPAG GABAergic cells reverse obesity in high-fat diet-induced obesity mice?
Targeting vlPAG GABAergic cells, specifically through CACNA2D1 overexpression, reverses high-fat diet-induced obesity in mice, presenting a potential novel therapeutic target for obesity.
May identify a novel neural target for obesity; leaves open clinical translation and human efficacy.
Overeating disorders largely contribute to worldwide incidences of obesity. Available treatments are limited. Here, we discovered that long-term chemogenetic activation of ventrolateral periaqueductal gray (vlPAG) GABAergic cells rescue obesity of high-fat diet–induced obesity (DIO) mice. This was associated with the recovery of enhanced mIPSCs, decreased food intake, increased energy expenditure, and inguinal white adipose tissue (iWAT) browning. In vivo calcium imaging confirmed vlPAG GABAergic suppression for DIO mice, with corresponding reduction in intrinsic excitability. Single-nucleus RNA sequencing identified transcriptional expression changes in GABAergic cell subtypes in DIO mice, highlighting Cacna2d1 as of potential importance. Overexpressing CACNA2D1 in vlPAG GABAergic cells of DIO mice rescued enhanced mIPSCs and calcium response, reversed obesity, and therefore presented here as a potential target for obesity treatment.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: